Centrient Pharmaceuticals Netherlands B.V.
Centrient Pharmaceuticals Netherlands B.V., a leading player in the pharmaceutical industry, is headquartered in the Netherlands and operates across various regions globally. Founded in 2017, the company has quickly established itself as a key provider of essential medicines, particularly in the areas of antibiotics and anti-infectives. Centrient is renowned for its innovative approach to manufacturing and supplying high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. Their commitment to sustainability and efficiency sets them apart in a competitive market. With a strong focus on meeting the needs of healthcare providers and patients, Centrient has achieved significant milestones, including expanding its product portfolio and enhancing its market presence. As a trusted partner in the healthcare sector, Centrient Pharmaceuticals continues to drive advancements in pharmaceutical solutions, reinforcing its position as a vital contributor to global health.
DitchCarbon Score
How does Centrient Pharmaceuticals Netherlands B.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Centrient Pharmaceuticals Netherlands B.V.'s score of 46 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Centrient Pharmaceuticals Netherlands B.V.'s reported carbon emissions
In 2023, Centrient Pharmaceuticals Netherlands B.V. reported total carbon emissions of approximately 142,740,000 kg CO2e for Scope 1, 141,369,000 kg CO2e for Scope 2, and 448,232,000 kg CO2e for Scope 3 emissions. The combined total for Scope 1 and Scope 2 emissions was about 284,109,000 kg CO2e. This data reflects a comprehensive approach to emissions reporting, including all three scopes. Centrient Pharmaceuticals has set ambitious reduction targets as part of its ESG Ambition 2021–2030. The company aims to achieve a 35% reduction in Scope 1 and Scope 2 emissions by 2025, using 2015 as the baseline year, and a 50% reduction by 2030. Additionally, they have reported a 7.5% reduction in emissions intensity (measured in tCO2e per tonne of product) for both Scope 1 and Scope 2 since 2021. The emissions data for Centrient Pharmaceuticals is cascaded from its parent company, Centrient Holding B.V., indicating a structured approach to sustainability across the corporate family. This commitment to reducing carbon emissions aligns with industry standards and reflects a proactive stance towards climate change mitigation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 121,708,000 | 000,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 242,430,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Centrient Pharmaceuticals Netherlands B.V. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
